sc291
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 2, 2023 (NCT05878184)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06294236 | Phase 1 | Apr 29, 2024 | Sana Biotechnology |
| NCT05878184 | Phase 1 | May 2, 2023 | Sana Biotechnology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sana Biotechnology | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1